Loading
Every dated change on the records linked to Rosai-Dorfman-Destombes disease, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Observation, because spontaneous regression is common.
Excisional biopsy with immunohistochemistry and MAPK pathway sequencing; FDG-PET/CT; MRI where neurological disease is suspected; immunoglobulins and autoimmune screen.
Cobimetinib (approved 2022 for histiocytic neoplasms) or trametinib.
Corticosteroids for rapid control; sirolimus with prednisone, cladribine, methotrexate or lenalidomide; rituximab for IgG4-associated disease.
Surgical excision or debulking; radiotherapy for unresectable localised disease (orbit, airway).
A milestone in how this cancer is treated.